Ceva Santé Animale

What Ceva Santé Animale does

Ceva Santé Animale is a French veterinary health company headquartered in Libourne, France, founded in 1989. The company researches, develops, produces, and markets pharmaceutical products, vaccines, and biologics across three core verticals: farm animals (poultry, cattle, swine, sheep, and goats), companion animals (dogs and cats), and wildlife. With €1.92 billion in 2025 turnover, operations across 47 countries, and 5,001–10,000 employees, Ceva is the world's fifth-largest animal health company. Product brands include FELIWAY (feline pheromone products), ReprodAction (livestock reproductive health), Vectormune and Transmune (poultry vaccines), plus acquired technologies such as the Aquilón swine dysentery vaccine and the Artemis rabies vaccine for wildlife.

Ceva's technology stack combines traditional veterinary pharmaceuticals with an emerging biotechnology layer acquired through inorganic moves. The 2024 Scout Bio acquisition added a pipeline of monoclonal antibodies and gene therapies targeting chronic pet diseases; the 2026 Aquilón CyL acquisition brought the first commercial vaccine against porcine dysentery (Brachyspira hyodysenteriae); and the 2022 Artemis Technologies acquisition added wildlife rabies vaccine capabilities. The company also offers connected smart solutions — Injector Manager and Farm Manager Bluetooth-enabled mobile applications for livestock management — representing its most digitally-oriented product surface.

The business model is product-sale driven: revenue is generated through direct sales to veterinary professionals and commercial livestock producers, distribution through veterinary wholesalers, and market-specific joint ventures. The May 2026 Ceva Bussan Animal Health JV with Mitsui & Co. illustrates a hybrid go-to-market combining direct control with local partner expertise. The company is privately held with Mérieux Equity Partners among its known investors, and has executed a sustained acquisition-led growth strategy funded by multiple institutional rounds, the latest led by Temasek in March 2025.

Name

Ceva Santé Animale

Legal name

Ceva Santé Animale

Website

https://ceva.com

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Ceva Santé Animale is a France-based, world's fifth-largest animal health company developing vaccines, biologics, and pharmaceuticals for farm animals, companion animals, and wildlife, operating across 47 countries with €1.92 billion in 2025 turnover.

Ownership category

akta.pro rank

Product category

Veterinary Pharmaceuticals and Animal Health

NAICS

Veterinary Services (54194), Veterinary Services (541940)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Veterinary Vaccines (Biologics) (HLAMAEAL)

akta.pro secondary industries

Livestock Vaccines (Cattle, Swine, Sheep & Goats) (HLAMAKAB), Companion Animal Vaccines (Dogs & Cats) (HLAMAKAA), Veterinary Vaccines (HLAIAEAH), Veterinary Pharmacy, Vaccine & Biologics Services (AFAEANAK), Vaccine Pharmacovigilance & Post-Market Surveillance (HLAMAKAN)

Keywords

• Veterinary pharmaceuticals
• Animal vaccines
• Livestock health solutions
• Pet therapeutics
• Veterinary biologics

Headquarters

HQ city

Libourne

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Veterinary pharmaceutical products: Revenue generated from sale of veterinary medicines, vaccines, and biologics for farm animals and companion animals. The company reported €1.92 billion turnover in 2025.
2. Japan market operations: Revenue from Japanese market through Ceva Bussan Animal Health JV, where BAH generated approximately €40 million in revenue in 2025

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Ceva Santé Animale researches, develops, produces, and markets veterinary pharmaceutical products and vaccines for farm animals (poultry, cattle, swine, sheep, goats), companion animals (dogs, cats), and wildlife. Its portfolio spans vaccines, biologics, pharmaceuticals, pheromone-based products, and connected smart equipment, distributed through veterinary professionals and distributors across 47 countries.

Product overview

Ceva Santé Animale is the world's fifth-largest animal health company offering a comprehensive portfolio of veterinary pharmaceuticals, vaccines, and smart solutions for both farm animals (poultry, cattle, sheep/goats) and companion animals. The product portfolio includes proprietary brands such as FELIWAY (pheromone-based behavior products for cats), ReprodAction (reproductive health), Vectormune and Transmune (poultry vaccines), alongside acquired technologies including Aquilón's swine dysentery vaccine and Artemis Technologies' rabies vaccine for wildlife. The company also provides equipment and smart solutions including Injector Manager and Farm Manager mobile applications. Ceva operates in 47 countries with 2025 turnover of €1.92 billion.

Differentiator

Problem solved

Functional benefit

Brands

• Injector Manager: Mobile application for injector management that connects to devices via Bluetooth
• Farm Manager

Products and services

• Farm Animals Solutions

Quantifiable outcome

• Reduced antibiotic use in livestock production through innovative vaccines and health solutions
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered core, moderate and minor.

• Aquilón CyLcoreStrategic or Co-development Partner · 1 June 2026Acquisition of biotech company Aquilón CyL, spin-off from University of León specializing in animal health. Developed first commercial vaccine against porcine dysentery caused by Brachyspira hyodysenteriae. Scientific team integrating into Ceva to reinforce R&D capabilities.
• Mitsui & Co.coreStrategic or Co-development Partner · 1 May 2026Joint venture Ceva Bussan Animal Health combining Mitsui's Bussan Animal Health (BAH) and Ceva Japan. Mitsui transferred 60% of BAH shares to Ceva, making Ceva controlling shareholder. BAH generated €40 million revenue in 2025. JV serves as consolidated platform for growth in Japanese animal health market.
• Scout BiocoreTechnology or Integration · 1 January 2024Acquisition of US-based Scout Bio to strengthen biotechnology expertise in pet therapeutics. Scout Bio had pipeline of monoclonal antibodies and gene therapies for chronic pet diseases.
• Artemis TechnologiesmoderateTechnology or Integration · 1 May 2022Acquisition of Canadian company Artemis Technologies known for rabies vaccine for wild animals. Strategic move to expand portfolio in North America and enhance access to innovative technology applicable to pets, wildlife, and livestock.
• International Egg FoundationminorStrategic or Co-development PartnerCeva joined the International Egg Foundation Partnership Programme supporting sustainable animal protein production through egg industry development.
• University of Sunshine Coast (Australia)moderateStrategic or Co-development PartnerCollaboration with University of Sunshine Coast in Brisbane to finance development of a vaccine against chlamydiosis in koalas, supporting conservation efforts for this endangered species.
• CNRS (France)minorStrategic or Co-development PartnerPartnership with CNRS to protect northern gannets against Highly Pathogenic Avian Influenza (HPAI), including GPS tracking and serological testing.
• Parc Pairi Daiza (Belgium)minorStrategic or Co-development PartnerSupport for avian influenza vaccination program at Pairi Daiza zoo (elected best zoo in Europe), in collaboration with Sciensano for serological and virological monitoring.
• University of Pretoria and University of Technology of Tshwane (South Africa)minorStrategic or Co-development PartnerSupport for pangolin conservation doctorate program including behavioral data collection and release protocols, supervised by African Pangolin Working Group.
• National Livestock and Fisheries Development Program (Saudi Arabia)moderateStrategic or Co-development PartnerCeva signed MoU with Saudi Arabia's National Livestock and Fisheries Development Program for collaboration in animal health sector.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Zoetis: World's largest pure-play animal health company, offering vaccines, parasiticides, diagnostics, and pharmaceuticals across companion and farm animals. Directly comparable to Ceva across species and product categories, with a meaningful scale advantage.
• Elanco Animal Health: Pure-play animal health company offering companion animal therapeutics, livestock vaccines, and farm animal pharmaceuticals. Direct peer to Ceva with comparable species coverage but a significantly larger revenue base following the Bayer Animal Health acquisition.
• Virbac: French-based global animal health company specializing in vaccines, parasiticides, and pharmaceuticals for companion and farm animals. Direct peer with comparable European heritage and overlapping product categories; previous employer of Ceva's incoming Deputy CEO.
• Vetoquinol: French-headquartered global animal health company focused on companion animals and livestock pharmaceuticals. Directly comparable as a similarly sized European pure-play animal health player with shared species and geographic overlap.
• Phibro Animal Health: Global animal health and nutrition company offering vaccines, parasiticides, and nutritional specialty products for livestock and poultry. Comparable mid-sized peer focused on farm animal segments where Ceva also has significant exposure.
• Dechra Pharmaceuticals: UK-based specialist animal health company focused on companion animal pharmaceuticals, particularly endocrinology and dermatology. Now owned by GSK but operating as a distinct animal health business with comparable product positioning to Ceva's companion animal portfolio.
• Norbrook: Privately held Northern Ireland-based veterinary pharmaceuticals manufacturer producing anti-infectives, anti-inflammatories, and parasiticides for companion and farm animals. Comparable mid-sized peer with similar product portfolio scope and European heritage.

Broad incumbents

• MSD Animal Health (Merck Animal Health): Animal health division of Merck & Co., one of the top global animal health companies offering vaccines, pharmaceuticals, and identification products across all major species. Operates as a broad incumbent within a larger human pharma parent.
• Boehringer Ingelheim Animal Health: Animal health business of Boehringer Ingelheim, a top-3 global player in veterinary vaccines and therapeutics across companion and livestock species. Broad incumbent operating within a larger human pharma group.

Emerging players

• IDEXX Laboratories: Global leader in veterinary diagnostics with companion animal practice software and water/livestock testing. Partial overlap with Ceva through companion animal health, but primarily diagnostics-focused rather than therapeutics/vaccines.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/CevaSanteAnimal
• LinkedInlinkedin.com/company/ceva-sante-animale

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries7 records

Funding overview

Funding rounds9 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A10 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ceva Santé Animale